Active Biotech Advances Tasquinimod Myelofibrosis Study After Initial Safety Cohort
Active Biotech AB (OMXSTO:ACTI) has completed the initial six-week safety evaluation for the first group of three patients in its Phase Ib/II study evaluating tasquinimod for myelofibrosis. The trial is progressing under the revised HOVON 172 study protocol.
During the evaluation period, one serious adverse event and dose-limiting toxicity was reported and successfully resolved. All three participants continue on the trial, indicating manageable tolerability for the adjusted dosage schedule.
The company is now moving forward by enrolling three additional patients in the next cohort. This step aims to verify the treatment's safety profile and determine the recommended dose for Phase II testing.
Key points
- Active Biotech completed the six-week safety evaluation for its first three-patient cohort in the tasquinimod trial.
- One serious adverse event was resolved, and all participants remain actively enrolled on the study.
- The trial is conducted under the amended HOVON 172 protocol for myelofibrosis treatment.
- Enrollment is opening for three more patients to confirm safety and select the Phase II dose.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the latest update on Active Biotech's tasquinimod study?
Active Biotech completed the first six-week safety evaluation for three patients in its Phase Ib/II myelofibrosis trial.
Were any side effects reported in the tasquinimod trial?
One serious adverse event was observed and resolved, and all three patients continue on the study.
What is the next phase for the Active Biotech trial?
Active Biotech is enrolling three more patients to confirm safety and set the Phase II dose.